Pipoxolan
Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent and anticancer agent. Pipoxolan modulates PI3K/AKT signaling pathways, and reduces the levels of Ras/MEK/p-ERK, MMP-2 and MMP-9. Pipoxolan inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators. Pipoxolan induces ROS generation, endogenous mitochondrial Apoptosis, and G0/G1 cell cycle arrest. Pipoxolan reduces cerebral infarction size and inhibits intimal hyperplasia. Pipoxolan can be used in research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia and lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 23744-24-3
- Formel: C22H25NO3
- Molecular Weight:351.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle MEK Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
MMP-9 |
MMP-2 |
HO-1 |
In Vitro
Pipoxolan (5-15 µM; 24, 48, 72 hr) potently inhibits PDGF-BB-stimulated migration of A7r5 vascular smooth muscle cells in a dose-dependent manner over 24, 48, and 72 hours[1].
Pipoxolan (5-15 µM; 48 hr pre-treatment; 8 hr migration period) inhibits PDGF-BB-stimulated migration of A7r5 vascular smooth muscle cells in a transwell assay, with 76.5% inhibition at the highest concentration[1].
Pipoxolan (5-15 µM; 48 hr) downregulates Ras, MEK, p-ERK, MMP-2, and MMP-9 protein levels in PDGF-BB-stimulated A7r5 vascular smooth muscle cells, with the greatest reduction in p-ERK (75%) at 15 µM[1].
Pipoxolan (1.6-100 μg/mL; 24 h) is cytotoxic to human TW206, HSC-3, and Cal-27 cells in vitro, with IC50 values of 13.13 μg/mL, 42.28 μg/mL, and 52.69 μg/mL respectively, and TW206 and HSC-3 cells are more sensitive than Cal-27 cells[2].
Pipoxolan (20 μg/mL; 2-6 h) induces apoptosis in human TW206 OSCC cells in a time-dependent manner, with detectable apoptosis at 2 h and maximal levels at 6 h of treatment with 20 μg/mL pipoxolan[2].
Pipoxolan (4-32 μM; 1 h pretreatment; 24 h LPS incubation) exhibits no significant cytotoxicity in LPS-stimulated RAW 264.7 murine macrophage cells[3].
Pipoxolan (4-32 μM; 1 h pretreatment; 24 h LPS incubation) dose-dependently inhibits LPS-induced nitrite production in RAW 264.7 murine macrophage cells, with 68.24% inhibition at 32 μM[3].
Pipoxolan (4-32 μM; 1 h pretreatment; 24 h LPS incubation) dose-dependently inhibits LPS-induced production of PGE2, TNF-α, and IL-6 in RAW 264.7 murine macrophage cells, with maximum inhibition of 90.73% (PGE2), 90% (TNF-α), and 95.27% (IL-6) at 32 μM[3].
Pipoxolan (1.6-50 μg/mL; 24 h) potently inhibits proliferation of human leukaemia HL-60 cells with an IC50 of 6.25 μg/mL, U937 cells with an IC50 of 12.5 μg/mL, and K562 cells with an IC50 of 25 μg/mL after 24 h, while showing no cytotoxicity against normal human PBMC at concentrations up to 50 μg/mL[4].
Pipoxolan (1.6-25 μg/mL; 2-48 h) arrests human leukaemia HL-60 cells in the G0/G1 phase in a time-dependent manner, reaching 62.0% at 48 h with 6.25 μg/mL, and induces dose-dependent sub-G1 apoptotic cell accumulation after 24 h[4].
Pipoxolan (3.2-25 μg/mL; 15 min-24 h) induces rapid, time- and concentration-dependent intracellular ROS generation in human leukaemia HL-60 cells, which is critical for its apoptotic activity, as NAC pretreatment blocks both ROS production and apoptosis[4].
Pipoxolan (2-10 μg/mL; 24 h) significantly inhibits proliferation of CL1-5 lung adenocarcinoma cells at 5 and 10 μg/mL after 24 h of incubation[5].
Pipoxolan (2-10 μg/mL; 24 h) does not induce apoptosis in CL1-5 or CL1-0 lung adenocarcinoma cells at concentrations of 2, 5, or 10 μg/mL after 24 h of incubation[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A7r5 vascular smooth muscle cells (VSMCs)
-
Concentration:5-15 µM
-
Incubation Time:24, 48, 72 hr
-
Result:Attenuated PDGF-BB-stimulated A7r5 cell migration in a dose-dependent manner at all time points tested.
Significantly reduced relative migration compared to PDGF-BB-only controls.
Exhibited the highest inhibition at the 15 µM concentration across all time points.
-
Cell Line:A7r5 vascular smooth muscle cells (VSMCs)
-
Concentration:5-15 µM
-
Incubation Time:48 hr pre-treatment; 8 hr migration period
-
Result:Significantly reduced the number of PDGF-BB-stimulated A7r5 cells migrating across the membrane.
Achieved percent inhibition of 46.2% at 5 µM, 62.2% at 10 µM, and 76.5% at 15 µM compared to PDGF-BB-only controls.
-
Cell Line:A7r5 vascular smooth muscle cells (VSMCs)
-
Concentration:5-15 µM
-
Incubation Time:48 h
-
Result:Reduced Ras protein levels by 21% at 5 µM, 24.75% at 10 µM, and 24% at 15 µM compared to PDGF-BB-only controls.
Reduced MEK protein levels by 21.67% at 5 µM, 21% at 10 µM, and 26.67% at 15 µM compared to PDGF-BB-only controls.
Reduced p-ERK protein levels by 50.33% at 5 µM, 51.67% at 10 µM, and 75% at 15 µM compared to PDGF-BB-only controls.
Reduced MMP-2 protein levels by 12.4% at 10 µM and 24.4% at 15 µM compared to PDGF-BB-only controls.
Reduced MMP-9 protein levels by 39.4% at 5 µM, 45.4% at 10 µM, and 36.6% at 15 µM compared to PDGF-BB-only controls.
-
Cell Line:human oral squamous cell carcinoma (OSCC) TW206, HSC-3 cells; human head and neck squamous cell carcinoma (HNSCC) Cal-27 cells
-
Concentration:1.6, 3.2, 6.25, 12.5, 25, 50, 100 μg/mL
-
Incubation Time:24 h
-
Result:Dose-dependently reduced cell viability in all three cell lines.
Reached IC50 values of 13.13 μg/mL for TW206 cells, 42.28 μg/mL for HSC-3 cells, and 52.69 μg/mL for Cal-27 cells.
Showed greater cytotoxicity to TW206 and HSC-3 cells than Cal-27 cells.
-
Cell Line:human OSCC TW206 and HSC-3 cells
-
Concentration:20 μg/mL (TW206 cells); 50 μg/mL (HSC-3 cells)
-
Incubation Time:2, 4, 8, 12, 24, 48 h
-
Result:Caused time-dependent increases in cytosolic cytochrome c, active caspase-9, active caspase-3, and cleaved PARP in HSC-3 cells, and did not alter caspase-8 expression.
Increased pro-apoptotic BAX protein expression and decreased anti-apoptotic BCL2 protein expression in both TW206 and HSC-3 cells after 24 h.
Caused time-dependent decreases in PI3K and phosphorylated AKT (pAKT) levels in both cell lines, with significant suppression after 24 h.
-
Cell Line:RAW 264.7 murine macrophage cells
-
Concentration:4-32 μM
-
Incubation Time:1 h pretreatment; 24 h LPS incubation
-
Result:Dose-dependently inhibited LPS-induced production of PGE2, TNF-α, and IL-6.
Inhibited PGE2 production by 90.73%, TNF-α production by 90%, and IL-6 production by 95.27% at 32 μM compared to LPS-only treated cells.
Showed statistically significant inhibition at all tested concentrations for each cytokine.
-
Cell Line:RAW 264.7 murine macrophage cells
-
Concentration:32 μM
-
Incubation Time:1 h pretreatment; 6 h LPS incubation
-
Result:Promoted LPS-induced translocation of Nrf2 from the cytoplasm to the nucleus, as visualized by increased nuclear Nrf2 fluorescence compared to LPS-only treated cells.
-
Cell Line:human leukaemia HL-60 cells
-
Concentration:1.6, 3.2, 6.25, 12.5, 25 μg/mL (24 h incubation); 6.25 μg/mL (2-48 h incubation)
-
Incubation Time:2, 6, 12, 24, 48 h
-
Result:Induced significant apoptosis (sub-G1 hypodiploid cells) with 6.25 μg/mL for 24 h.
Caused dose-dependent increases in sub-G1 cells at 12.5, 25 μg/mL after 24 h.
Caused time-dependent accumulation of cells in the G0/G1 phase: 48.7% at 12 h, 58.1% at 24 h, and 62.0% at 48 h, all statistically significant compared to controls.
In Vivo
Pipoxolan (10-30 mg/kg; p.o.; daily; 28 days starting on the day of ligation) dose-dependently reduces carotid artery ligation-induced intimal hyperplasia in male ICR mice, with 30 mg/kg (p.o., daily for 28 days) achieving a 47.20% reduction in the I/M ratio and 62.40% inhibition of PCNA-positive cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 225-275 g, transient focal cerebral ischemia-reperfusion model)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; single dose 1 hour pre-ischemia
-
Result:Reduced cerebral infarction area by 43.18%, neurological deficit score by 31.25%, TUNEL-positive cells by 31.25%, and cleaved caspase-3-positive cells by 37.18%.
Reduced cerebral infarction area by 73.43%, neurological deficit score by 46.88%, TUNEL-positive cells by 46.88%, and cleaved caspase-3-positive cells by 63.44%.
Did not alter mean arterial pressure or cerebral blood flow compared to controls.
-
Animal Model:ICR (male, 20-25 g, left common carotid artery ligation-induced model)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; daily; 28 days starting on the day of ligation
-
Result:Reduced the intima/media (I/M) ratio by 24.21% and inhibited PCNA-positive cells by 42.11%.
Reduced the intima/media (I/M) ratio by 47.20% and inhibited PCNA-positive cells by 62.40%.
Chemical Information
-
CAS. Nr. 23744-24-3
-
Molecular Weight 351.45
-
Formel C22H25NO3
-
SMILES
O=C1OC(OC1(C=2C=CC=CC2)C=3C=CC=CC3)CCN4CCCCC4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
[1]. Chen YF, et al. Pipoxolan ameliorates cerebral ischemia via inhibition of neuronal apoptosis and intimal hyperplasia through attenuation of VSMC migration and modulation of matrix metalloproteinase-2/9 and Ras/MEK/ERK signaling pathways. PLoS One. 2013;8(9):e75654. Published 2013 Sep 24. [Content Brief]
[2]. Chou PY, et al. Pipoxolan Exhibits Antitumor Activity Toward Oral Squamous Cell Carcinoma Through Reactive Oxygen Species-mediated Apoptosis. Anticancer Res. 2017;37(11):6391-6400. [Content Brief]
[3]. Lin YH, et al. Pipoxolan suppresses the inflammatory factors of NF-κB, AP-1, and STATs, but activates the antioxidative factor Nrf2 in LPS-stimulated RAW 264.7 murine macrophage cells. Environ Toxicol. 2020;35(12):1352-1363. [Content Brief]
[4]. Sheu MJ, et al. Pipoxolan inhibits proliferation of HL-60 human leukaemia cancer cells by arresting the cell cycle at the G0/G1 phase. Clin Exp Pharmacol Physiol. 2010;37(5-6):605-612. [Content Brief]
[5]. Lee MM, et al. Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2. Chem Biol Interact. 2015;236:19-30. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Pipoxolan
- 23744-24-3
- Ras
- MEK
- ERK
- PI3K
- Akt
- MMP
- Keap1-Nrf2
- Heme Oxygenase (HO)
- Reactive Oxygen Species (ROS)
- Apoptosis
- vascular smooth muscle cells
- RAW 264.7 murine macrophage cells
- lung cancer
- CL1-5 lung adenocarcinoma cells
- A7r5 vascular smooth muscle cells
- PI3K/AKT signaling pathways
- HL-60 cells
- leukaemia
- Ras/MEK/ERK signaling pathways
- oral squamous cell carcinoma
- Inhibitor
- inhibitor
- inhibit